PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 2128967
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 2128967
Acromegaly Treatment Market size was valued at US$ 1,807.6 Million in 2025, expanding at a CAGR of 6.5% from 2026 to 2033.
The acromegaly treatment market comprises a wide range of drug therapies and therapy monitoring that aids biochemical control when surgery may not be appropriate, unsuccessful, or ineffective. The key products used in its treatment are somatostatin analogs, growth hormone receptor antagonists, dopamine agonists, and newer endocrine therapies. The choice of treatment is now more firmly directed by parameters such as the rate of response in terms of IGF-1, tumor characteristics, tolerability, complexity, burden of dosing, and past treatment experience. In 2025, therapeutic choices remain broad class-wise, while oral delivery has increased market significance after the FDA approval of paltusotine for use in the USA. Somatostatin analogs, dopamine agonists, and pegvisomant are a few of those recorded by the FDA as therapies. Therefore, market share is no longer about offering treatments but about effectiveness, convenience, and individuality.
Acromegaly Treatment Market- Market Dynamics
Oral Administration Is Reshaping Treatment Convenience and Product Competition
A strong near-term driver is the trend toward less burdensome administration via an oral formulation. In September 2025, the FDA approved paltusotine, the first once-daily oral therapy for the treatment of acromegaly in adult patients. The FDA approval was based on two pivotal phase III trials, which enrolled 169 patients across 73 centers in 18 countries, demonstrating the drug's efficacy: biochemical control at week 24 was achieved in 56% of treated patients in one trial and 83% in another, compared to 5% and 4% with placebo, respectively. As a result, the commercial success of convenient once-daily dosing gained significant momentum, creating a challenge for other injectable agents on the market. In this context ease of administration is a relevant and evolving competitive factor.
The Global Acromegaly Treatment Market is segmented on the basis of Product Type, Route of Administration, Distribution Channel, Treatment Type, and Region.
By product type, the growth hormone receptor antagonists are mainly indicated in cases where biochemical control is not achieved by using other forms of medication, with pegvisomant causing a decrease in IGF-1 by inhibiting the growth hormone receptor. Somatostatin receptor agonists form the main category of pharmacotherapy due to their ability to inhibit growth hormone secretion, while the use of dopamine agonists is usually more targeted, given that they are less effective in many individuals. Paltusotine, an oral form of the somatostatin receptor agonist branded Palsonify, came onto the market in 2025 after being approved by the FDA. This approval provided a once-daily oral form of medication for adults with acromegaly who do not respond to surgery or for whom surgery is not an option.
By Route of Administration, medical laboratory testing is the primary segment for diagnosing acromegaly, where IGF-1 levels are assessed for screening purposes, while growth hormone suppression tests confirm the diagnosis. Similarly, medical imaging is a critical component of evaluation, where MRI is typically used to visualize the pituitary gland and determine the tumor's size and location. Both laboratory tests and imaging are used complementarily, with the former evaluating hormone levels and establishing the diagnosis, while the latter determines the tumor's characteristics. In 2025, FDA trials for paltusotine used IGF-1 levels as the main indicator of biochemical response to treatment. Therefore, medical testing is the cornerstone of evaluating acromegaly, which guides clinicians in the selection of pharmacological interventions.
Acromegaly Treatment Market- Geographical Insights
North America remains leading market due to the presence of well-established endocrine therapeutics, regulatory activity, specialized care, and commercialization of innovative modes of therapy. In particular, in September 2025, the FDA approved paltusotine after two pivotal phase III trials were completed across 73 centers and 169 patients in 18 countries. This led to the first FDA-approved once-daily oral therapy for acromegaly. According to Crinetics, the company's sales force contacted more than 95% of key payers and target physicians during the product launch period. This specialty-centric approach helped the company achieve a significant foothold in the market. North America is, therefore, an important base for innovative and convenient modes of therapy.
Europe is an important market due to the presence of well-established treatment centers, a network of specialist physicians, and access to established long-acting somatostatin analogs. According to Ipsen, Somatuline Autogel/Depot was available in nearly 70 different countries worldwide at the end of 2025. The company also reported that 52.1% of the 2025 Somatuline sales were made in North America, thus highlighting the role of Europe as part of a global supply and sales network, rather than a stand-alone regional market. As such, the European market is mainly influenced by the availability of treatment specialties, the use of existing injectable therapies, and the shift towards more convenient approaches.
Market competition in the treatment of acromegaly now revolves around mechanisms of action, biochemical control, administration frequency, tolerability, and administration convenience. Long-acting somatostatin receptor agonists will continue to play an important role due to the mechanism involved in biochemical disease control, whereas pegvisomant represents an alternative method of disease management through a growth hormone receptor antagonist. Oral medication administration has gained increasing importance with the FDA approval of Palsonify (paltusotine) in September 2025, an orally administered somatostatin receptor agonist taken on a daily basis. The new option introduces greater administration convenience compared with injectable therapies and may intensify competition regarding adherence, patient preference, treatment switching, and long-term disease management.
In September 2025, Crinetics Pharmaceuticals received FDA approval for Palsonify (paltusotine) for the treatment of acromegaly in adults who are unsuitable for surgery or have had an inadequate response to surgery. The new therapy was the first once-daily oral treatment for acromegaly in the United States, differentiating itself through the convenience of administration.
In November 2025, Crinetics announced that Palsonify had been launched in the U.S., with the company's field force having engaged with over 95% of key care providers. Early market feedback suggested that the product was being adopted by both switchers and new users, providing commercial validation for the oral formulation